All Stories

  1. A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening
  2. Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma
  3. Advancing Non-Invasive Colorectal Cancer Screening: Exploring the Potential of Monoclonal Antibody L2A5
  4. Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells
  5. ABCB1 C1236T, G2677TA and C3435T Genetic Polymorphisms and Antidepressant Response Phenotypes: Results from a Portuguese Major Depressive Disorder Cohort
  6. Stool Glycoproteomics Signatures of Pre-Cancerous Lesions and Colorectal Cancer
  7. Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer
  8. Minimizing false positives for CTC identification
  9. Multilevel Plasticity and Altered Glycosylation Drive Aggressiveness in Hypoxic and Glucose-Deprived Bladder Cancer Cells
  10. MicroRNA Biomarkers as Promising Tools for Early Colorectal Cancer Screening—A Comprehensive Review
  11. Syndecan-4 is a maestro of gastric cancer cell invasion and communication that underscores poor survival
  12. Discriminating Epithelial to Mesenchymal Transition Phenotypes in Circulating Tumor Cells Isolated from Advanced Gastrointestinal Cancer Patients
  13. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion
  14. Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer
  15. Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification
  16. Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies
  17. TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
  18. Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications
  19. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
  20. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer
  21. CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications
  22. Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology
  23. Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
  24. TargetedO-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours
  25. Reference Genes for Addressing Gene Expression of Bladder Cancer Cell Models under Hypoxia: A Step Towards Transcriptomic Studies
  26. IL6-174G > C genetic polymorphism influences antidepressant treatment outcome
  27. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension
  28. The role of IL18-607C > A and IL18-137G > C promoter polymorphisms in antidepressant treatment phenotypes: A preliminary report
  29. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics
  30. FAS -670A>G genetic polymorphism Is associated with Treatment Resistant Depression
  31. New trends in guided nanotherapies for digestive cancers: A systematic review
  32. The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population
  33. Su1939 Influence of Genetic Polymorphisms in Prostaglandin E2 (PGE2) Pathway on mRNA Expression of COX-2, Hpgd, Abcc4 and Slco2a1 Genes in Colorectal Tumors
  34. P53 and Cancer-Associated Sialylated Glycans Are Surrogate Markers of Cancerization of the Bladder Associated with Schistosoma haematobium Infection
  35. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure11The first author has a PhD Grant (SFRH/BD/43399/2008) and J.A.F. has a Postdoctoral Grant (SFRH/BPD/66288/2009) from ...
  36. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer
  37. Common Genetic Polymorphisms in the ABCB1 Gene Are Associated with Risk of Major Depressive Disorder in Male Portuguese Individuals
  38. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy
  39. Frequency of TERT promoter mutations in human cancers
  40. Overexpression of tumour-ssociated carbohydrate antigen sialyl-Tn in advanced bladder tumours
  41. Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
  42. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa
  43. IL-4 and TNF-α Polymorphisms Are Associated with Risk of Multiple Superficial Tumors or Carcinoma in situ Development
  44. Association between FAS polymorphism and prostate cancer development